2008
DOI: 10.1185/03007990802138731
|View full text |Cite
|
Sign up to set email alerts
|

Current status of cholesterol goal attainment after statin therapy among patients with hypercholesterolemia in Asian countries and region: the Return on Expenditure Achieved for Lipid Therapy in Asia (REALITY-Asia) study

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2

Citation Types

6
52
0
2

Year Published

2009
2009
2019
2019

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 66 publications
(60 citation statements)
references
References 35 publications
6
52
0
2
Order By: Relevance
“…LDL-C after 12 months 17) . However, the Lipid Treatment Assessment Project 2 (L-TAP2) study 19) , reported a higher rate of LDL-C goal attainment than the combined CEPHEUS studies.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…LDL-C after 12 months 17) . However, the Lipid Treatment Assessment Project 2 (L-TAP2) study 19) , reported a higher rate of LDL-C goal attainment than the combined CEPHEUS studies.…”
Section: Discussionmentioning
confidence: 99%
“…Statins are the mainstay of lipid-lowering drug (LLD) therapy and have been shown to reduce both LDL-C levels and CV risk in clinical trials [9][10][11][12][13][14][15][16] . Despite the significant increase in the number of patients treated with statins and other LLDs over the past decade, surveys have shown that relatively few individuals eligible for treatment attain their recommended LDL-C level [17][18][19] . …”
mentioning
confidence: 99%
“…[13][14][15][16][17] Similarly, a study of dyslipidaemia management in South Asia including China, South Korea, Malaysia, and Singapore revealed that only 48% of patients attained pre-defined low-density lipoprotein-cholesterol goals. 18 Similar to other chronic conditions, the reasons for poor (lipid) control are multifactorial and may include patient, physician, and health care delivery factors. Among them, suboptimal medication augmentation has been identified as an important physician factor.…”
Section: Discussionmentioning
confidence: 99%
“…The National Health Insurance (NHI), as the backbone of the healthcare system in Taiwan, provides universal medical coverage for beneficiaries (>99% of the population) with a small portion paid by the users; therefore, financial concerns may not be a major issue. However, the under-treatment of hypercholesterolemia in Taiwan was more prevalent compared with other Asian countries 4,6,7) . Because enhanced prescription coverage has been shown to improve medication persistence and to reduce vascular events 17) , such discrepancy occurring in a population that is well covered by the healthcare insurance program may largely reflect a lack of awareness and poor compliance.…”
Section: Characteristics Of Physicians and Practicementioning
confidence: 99%
“…Despite the treatment benefits demonstrated by clinical trials and therapeutic targets advocated by academic societies, the majority of patients fail to achieve the LDL-C targets recommended by the practicing guidelines, particularly in the high-risk patients [4][5][6] . Suboptimal control is directly related to the risk level of individual patients, including the target set accordingly and the baseline LDL-C level 6,7) , and inadequate pharmacological treatment, including under-prescription 8) , inappropriate dosing and potency 9) , and non-compliance of both patients and physicians [5][6][7] . In addition to patient characteristics and compliance to lipid-lowering medications, physician characteristics and the administration policy were also associated with under-treatment and non-treatment [10][11][12] .…”
Section: Characteristics Of Physicians and Practicementioning
confidence: 99%